Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients

Lung Cancer

Volumn 53, Issue 3, 2006, Pages 339-345

  Lee, Dae Ho ^a   Han, Ji Youn ^b   Kim, Heung Tae ^b   Lee, Jin Soo ^b  

^a Asan Medical Center   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Gefitinib; Non small cell lung cancer; Predictors; Survival; Tumor response

Indexed keywords

GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RETROSPECTIVE STUDY; SMOKING; SOUTH KOREA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; KOREA; LUNG NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33747075791     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.05.015     Document Type: Article

References (32)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
2. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
3. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
4. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
5. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
7. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
8. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancer from "never-smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
9. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene copy number, gene mutations and protein level predict outcome to gefitinib therapy in advanced non-small cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
10. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al. Increased EGFR gene copy numbers detected by FISH associates with increased sensitivity to gefitinib in patients with bronchioalveolar carcinoma cell types-a Southwest Oncology Group study. J Clin Oncol 23 (2005) 6838-6845
11. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolinin S., Ceresoli G.L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23 (2005) 5007-5018
12. Travis W.D., Colby T.V., Corrin B., Shimasato Y., Brambilla E., et al. Histological typing of lung and pleural tumors. 3rd ed. (1999), Springer, Berlin
13. Ebright M.I., Zakowski M.F., Martin J., Venkatraman E.S., Miller V.A., Bains M.S., et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 74 (2002) 1640-1646
14. WHO. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization; 1979.
15. Miller A.J. Subset selection in regression (1990), Chapman and Hall, London
16. Sauerbrei W. Comparison of variable selection procedures in regression models-a simulation study and practical examples. In: Michaelis J., Hommel G., and Wellek S. (Eds). Europäische Perspektiven der Medizinischen Informaitk, Biometrie und Epidemiologie (1993), MMV, Munchen 108-113
17. Jänne P.A., Gurubhagavatula S., Yeap B.Y., Lucca J., Ostler P., and Skarin A.T. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44 (2004) 221-230
18. Kaneda H., Tamura K., Kurata T., Uejima H., Nakagawa K., and Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 46 (2004) 247-254
19. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 1103-1109
20. Ahrendt S.A., Decker P.A., Alawi E.A., Zhu Y.R., Sanchez-Cespedes M., Yang S.C., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92 (2001) 1525-1530
21. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
22. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M., et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98 (2002) 310-315
23. Dai Q., Ling Y.H., Lia M., Zou Y.Y., Kroog G., Iwata K.K., et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 11 (2005) 1572-1578
24. Kobayashi S., Boggon T., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352 (2005) 786-792
25. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
26. Toyooka S., Kiura K., and Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 352 (2005) 2136 author reply
27. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
28. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
29. Hilsenbeck S.G., Raub Jr. W.A., and Sridhar K.S. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol 16 (1993) 301-309
30. Ries L.A. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. Semin Surg Oncol 10 (1994) 21-30
31. Shanafelt T.D., Loprinzi C., Marks R., Novotny P., and Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?. J Clin Oncol 22 (2004) 1966-2005
32. Lee D.H., Han J.Y., Lee H.G., Lee J.J., Lee E.K., Kim H.Y., et al. Gefitinib as a first-lie therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11 (2005) 3032-3037